Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 195 – 6 SEPTEMBER 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 171/24 and 173/24, respectively. Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Martin Badsted, Chief Financial Officer, tel.: +45 33 42 05 26, e-mail: mba@norden.com

Registration of the capital increase and completion of the rights issue

Nasdaq First North Growth Market Denmark Company announcement no. 17-2024 Aalborg, 6 September, 2024 This message contains inside information Announcement regarding registration of the capital increase and completion of the rights issue In continuation of the company announcement no. 16-2024 on the results of the offering of new shares as described and announced by MapsPeople in the company announcement no. 14-2024, MapsPeople A/S hereby announces that the share capital increase and the updated articles of association has been registered with the Danish Business Authority.

Gradientech starts US 510(k) study for QuickMIC® at clinical sites

The diagnostics company Gradientech today announces to have started the 510(k) clinical study for the QuickMIC® system for ultra-rapid antibiotic susceptibility testing at the first two clinical sites, both well-renowned hospitals in the US.Following successful pre-clinical evaluation studies of the QuickMIC system in the US last year, and with a breakthrough device designation by the FDA, the 510(k) study of QuickMIC and its first gram-negative panel is now initiated at clinical sites in the US. The focus of the clinical study will be antibiotic susceptibility testing results for gram-

AddSecure and Astrata showcase integrated fleet solutions to boost efficiency and safety at IAA Hannover

The joint trade fair appearance will spotlight Fleet and Transport Management Systems for enhanced efficiency and reliability, as well as the AI video-based fleet safety system RoadView.AddSecure , a leading European provider of secure IoT connectivity and end-to-end solutions, and industry leader in fleet and transport management solutions across Europe, will exhibit at IAA Hannover alongside its latest addition to the AddSecure Group, the European telematics division of Astrata.   In June 2024, AddSecure announced the acquisition of Astrata Europe B.V.,

Read original

Nordea Bank Abp’s financial reporting in 2025

Nordea Bank AbpStock exchange release – Financial calendar6 September 2024 at 10.00 EET Nordea Bank Abp will publish the following financial reports in 2025: · Fourth-quarter and full-year results 2024 on 30 January 2025 · First-quarter results 2025 on 16 April 2025 · Second-quarter and half-year results 2025 on 17 July 2025 · Third-quarter and January-September results 2025 on 16 October 2025 The Annual Report for 2024 will be published in week 9, 2025, at the latest, and the Capital and Risk Management Report for 2024 in week 10, 2025, at the latest. The Annual

Tecnotree Corporation updates guidance and dividend policy

Tecnotree Corporation Stock Exchange Release 6 September 2024 at 10:00 EESTTecnotree Corporation will be hosting an Investor and Analyst Connect virtual event later today as detailed on the company website. The event will cover certain forward looking financial guidance that Tecnotree would like to inform the market of. Tecnotree will reiterate its guidance for 2024 while updating its outlook and guidance for 2025. · Revenue to be higher by 2%-7% in 2024 as compared to 2023 · Operating profit (EBIT) to be higher by 7%-15% in 2024 as compared to 2023 · Free cash flow (FCF)

Construction of the southern part of the main building of the Laakso Joint Hospital begins - EUR 174 million will be entered into SRV’s order backlog

SRV GROUP PLC                          INVESTOR NEWS                        6 SEPTEMBER 2024 at 10:00 EEST Construction of the southern part of the main building of the Laakso Joint Hospital begins - EUR 174 million will be entered into SRV’s order backlog SRV, Kiinteistöosakeyhtiö Laakson yhteissairaala (real estate company), the Laakson LATU consortium, the Unitas consortium and Granlund have signed a contract regarding the southern part of the main building of the Laakso Joint Hospital. The order is valued at about EUR 183 million, of which SRV’s share is approximately EUR 174

HANZA to implement sustainable manufacturing solution for Mitel

HANZA has signed a strategic agreement with Mitel Networks Corp, a Canadian telecommunications company, under which HANZA will relocate manufacturing from China to Europe. This relocation of manufacturing is directly in line with Mitel's sustainability goals and will be implemented under the MIG™ concept (Manufacturing Solutions for Increased Growth).Under the agreement, HANZA will consolidate Mitel's production to HANZA's manufacturing cluster in Sweden in order to optimize the supply chain for flexibility and cost. The relocation closer to end markets will reduce transportation emissions

STORA ENSO: Harvesting site inspections in Finland completed, harvesting resumed – Earlier notified stream site inspected by environmental authority

STORA ENSO OYJ PRESS RELEASE 6 September 2024 at 9:45 EESTStora Enso has completed its inspections of harvesting sites in Finland with high nature values. The inspections took place following the environmental violation in Hukkajoki, Finland on 15 August. The inspections show that no additional non-compliance cases have been detected in the assessed areas. As a result, harvesting operations at all inspected sites in Finland have been resumed.During the inspections, the operational guidelines, harvesting plans, and risks related to the harvesting sites were reassessed. In addition to the

Himalaya Shipping Ltd. (HSHP) – Commercial Update and Key Information Relating to the Cash Distribution for August 2024

Hamilton, Bermuda, September 6, 2024 Commercial update: In August 2024, Himalaya Shipping Ltd. (“Himalaya,” or the “Company”) achieved average time charter equivalent (“TCE”) earnings of approximately US$33,500 per day, gross[1], including average daily scrubber and LNG benefits on eleven vessels of approximately US$1,600 per day. The Company’s two vessels trading on fixed time charters earned approximately US$36,500 per day, gross, including average daily scrubber and LNG benefits on one vessel. The Company’s ten vessels trading on index-linked time charters earned approximately

White Pearl Technology Group to start reporting quarterly and updates the Financial Calendar

White Pearl Technology Group (WPTG) is introducing quarterly reports into its financial practice, starting with Q3 2024. This change aims to provide more frequent and timely information to shareholders and the investment community.Updated Financial Calendar · Q3 Report 2024: November 25th, 2024 · Q4 Report 2024: February 25th, 2025 · Annual Report 2024: April 28th, 2025 · Q1 Report 2025: May 26th, 2025 · Q2 Report 2025: August 25th, 2025 You can find the updated Financial Calendar on www.whitepearltech.com "This is a natural step for White Pearl Technology Group to

BiBB’s CEO to BioStock: “Zagreb confirms good samples and short learning curve”

The clinical introduction is in full swing for BiBBInstruments. The company’s first electric-driven biopsy instrument, EndoDrill GI, continues to impress with high-quality tissue samples, most recently at an introduction of EndoDrill GI at the University Hospital in Zagreb. Meanwhile, the European Patent Office announced the intention to grant the patent application for the EndoDrill technology. BioStock spoke to BiBB’s CEO Fredrik Lindblad to find out more.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/bibbs-ceo-zagreb-confirms-

Sectra’s three-month interim report 2024/2025: Increased recurring revenue led to a strong first quarter

Press release – Linköping, September 6, 2024 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) is continuing to grow with satisfied customers. Sales and operating profit were the highest the Group has ever reported for a first quarter. This trend was due in part to a more even distribution across quarters as a result of increased recurring revenue and growing volumes. At the same time, these figures are no longer being boosted by currency effects.First quarter (May–July 2024) in figures · Contracted order bookings decreased 79.3% to

Finnair Traffic Performance in August 2024

Finnair Plc                 Investor News               6 September 2024 at 9:00 a.m. EESTOnce again over million passengers as capacity increased year-on-year, strong cargo performanceIn August, Finnair carried 1,062,400 passengers, which is 9.5% more than in August 2023. The overall capacity, measured in Available Seat Kilometres (ASK), increased in August by 9.3% year-on-year as additional narrow-body capacity was deployed by Finnair after the wet lease outs to British Airways ended in March 2024. In addition, the capacity growth in Asian traffic was strong. If wet lease outs are

BlueNord: Preliminary Production for August 2024

Oslo, 6 September 2024: BlueNord ASA ("BlueNord" or the "Company") has today announced its preliminary production figures for August 2024. The Company had a preliminary production in August of net 27.0 mboepd of which 1.5 mboepd is from the Harald field which has had a stable production through the new Tyra facilities. The production during the month from the Dan, Gorm and Halfdan hubs continues to be strong with a preliminary high average uptime of 94% and with a positive response from the Skiold gas acceleration project on the Gorm hub. This information is subject to disclosure

New report reveals children of migrants bear the brunt of climate change-related migration in Southeast Asia

A new report from World Vision shows how migration in the context of climate change is profoundly affecting the lives of children in Southeast Asia, drawing on 92 first-hand accounts from child migrants, children who stayed behind when parents migrated, parents and older caregivers, as well as interviews with local leaders and experts. Photo: World Vision The report, produced in partnership with the Stockholm Environment Institute (SEI) Asia Centre, vividly depicts the deepening poverty, deprivation and debt burdens in rural communities that lead people to migrate in distress;

Lack of workplace support after medication errors can worsen outcomes among healthcare professionals

Psychological distress is the most common negative outcome experienced by healthcare professionals after making medication errors, according to a new study from the University of Eastern Finland. After such events, turnover intentions and absenteeism were more common among those experiencing inadequate organisational support and so called second victim distress. During this past decade, an abundance of research has been conducted regarding the prevalence and severity of the second victim phenomenon. The term “second victim”, coined by Dr. Albert Wu from Johns Hopkins University, refers

Mandatory Notification of Trade - Primary Insiders

Kongsberg, September 6, 2024: Christian Johansson, Chief Financial Officer and primary insider of Kongsberg Automotive ASA has purchased 100,000 shares in the company at an average price of NOK 1.46 on September 5, 2024. After the purchase, Christian Johansson holds 200,000 shares in Kongsberg Automotive ASA. Please refer to the attached notification of trading for further details.This information is subject to the disclosure requirements in article 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the Norwegian Securities Trading Act.

Noble Corporation plc announces major shareholder notification

SUGAR LAND, TEXAS, September 5, 2024 /CNW/ - Pursuant to Section 30 of the Danish Capital Markets Act, Noble Corporation plc ("Noble") (CSE: NOBLE, NYSE: NE) hereby announces the receipt of a major shareholder notification from APMH INVEST A/S.   On September 5, 2024, APMH INVEST A/S, acting on behalf of itself and its ultimate owner A.P. MØLLER OG HUSTRU CHASTINE MC-KINNEY MØLLERS FOND TIL ALMENE FORMAAL, notified Noble that APMH INVEST A/S’ holding of A ordinary shares in Noble corresponds to 17.35% of the voting rights and 17.35% of total share capital in Noble. APMH INVEST A/S

Correction of press release published on 3 September 2024 regarding first commercial order on a TSE SYSTEM

Scandinavian ChemoTech published a press release on 3 September 2024 regarding a first commercial order on a TSE SYSTEM. In the press release, the counterparty’s name was mentioned which was not allowed under the agreement with the counterparty. Below is a correct press release without the counterparty’s name and a clarification that the order of the TSE system includes consumables.   Animal Care Receives its First Commercial Order for a TSE System from a Large Animal Clinic in Sweden   Scandinavian ChemoTech’s subsidiary Vetiqure AB, proudly announces an order, for a complete

Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load

The study, which has now been completed, is an independent, investigator-initiated, randomised, double-blind placebo study led by Professor Glen Davison, Head of School of Sport and Exercise Sciences at the University of Kent in England. The secondary endpoints have now been reported as significant. All the results are official on the trial registry site: https://doi.org/10.1186/ISRCTN18133939.The study involved 164 endurance athletes who used either ColdZyme or placebo when experiencing upper respiratory tract infection symptoms. The difference between ColdZyme and placebo proved

There are no items matching the current filter
There are no more items matching the current filter
Back to top